Literature DB >> 24421551

Doxylamine succinate/pyridoxine hydrochloride.

Dennis J Cada1, Kendra Demaris2, Terri L Levien3, Danial E Baker4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2013 monograph topics are afatinib, ferric carboxymaltose, cangrelor, vedolizumab, and albiglutide. The DUE/MUE is on afatinib.

Entities:  

Year:  2013        PMID： 24421551      PMCID： PMC3857125          DOI： 10.1310/hpj4809-762

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  9 in total

1.  ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy.

Authors: 
Journal:  Obstet Gynecol       Date:  2004-04       Impact factor: 7.661

Review 2.  Clinical practice. Nausea and vomiting in pregnancy.

Authors:  Jennifer R Niebyl
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

3.  Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).

Authors:  Simerpal Kaur Gill; Facundo Garcia-Bournissen; Gideon Koren
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

4.  Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy.

Authors:  Ilan Matok; Shannon Clark; Steve Caritis; Menachem Miodovnik; Jason Umans; Gary Hankins; Gideon Koren
Journal:  J Clin Pharmacol       Date:  2013-01-24       Impact factor: 3.126

5.  Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy.

Authors:  Maged M Costantine; Ilan Matok; Guisseppe Chiossi; Shannon Clark; Menachem Miodovnik; Jason G Umans; Steve Caritis; Gary D V Hankins; Gideon Koren
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

6.  Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.

Authors:  Gideon Koren; Shannon Clark; Gary D V Hankins; Steve N Caritis; Menachem Miodovnik; Jason G Umans; Donald R Mattison
Journal:  Am J Obstet Gynecol       Date:  2010-09-16       Impact factor: 8.661

7.  Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy.

Authors:  Liat Ashkenazi-Hoffnung; Paul Merlob; Bracha Stahl; Gil Klinger
Journal:  Isr Med Assoc J       Date:  2013-01       Impact factor: 0.892

8.  Bendectin and birth defects. II: Ecological analyses.

Authors:  Jeffrey S Kutcher; Arnold Engle; Jacqueline Firth; Steven H Lamm
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-02

9.  Review of NVP and HG and Early Pharmacotherapeutic Intervention.

Authors:  Shannon M Clark; Maged M Costantine; Gary D V Hankins
Journal:  Obstet Gynecol Int       Date:  2011-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.